Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

2022672 citationsJournal Articlegreen Open Access

Authors

Eva Versteijne · Amsterdam University Medical Centers

Jacob L. van Dam · Erasmus MC Cancer Institute

Mustafa Suker · Erasmus MC Cancer Institute

Quisette P. Janssen · Erasmus MC Cancer Institute

Karin Groothuis · Netherlands Comprehensive Cancer Organisation

Janine M. Akkermans-Vogelaar · Netherlands Comprehensive Cancer Organisation

Marc G. Besselink · Amsterdam University Medical Centers

Abstract

Neoadjuvant gemcitabine-based chemoradiotherapy followed by surgery and adjuvant gemcitabine improves OS compared with upfront surgery and adjuvant gemcitabine in resectable and borderline resectable pancreatic cancer.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cholangiocarcinoma and Gallbladder Cancer Studies Pancreatitis Pathology and Treatment

Publication Details

Published in: Journal of Clinical Oncology

Volume 40, Issue 11, pp. 1220-1230

DOI: 10.1200/jco.21.02233

Field-Weighted Citation Impact: 66.09

Command Palette

Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial

Authors

Abstract

Topics & Keywords

Publication Details